ADC Therapeutics SA, the innovative anti-cancer therapeutics business, has floated on the New York Stock Exchange. Demand for the issue was high with an upsized placing and shares trading at an immediate premium.
ADC Therapuetics announces positive results from pivotal Phase 2 clinical trial of its lead therapeutic.
BBC features the life transforming impact of Oxsight Crystal smart glasses for a patient with Usher’s disease.
ADC Therapeutics Announces First Patients Dosed in Phase I/II Clinical Trial of ADCT-602 in Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
Phico Therapeutics awarded Innovate UK funding for £1.4 million ($1.87M) antibacterial therapy project.
UK China Enterprise joins Puhua Capital in backing Oxsight – an Oxford spin-out set to benefit people suffering from eyesight impairment with its intelligent smart glasses technology.
ET Capital is appointed manager of UK China Enterprise a fund exploiting the potential of UK innovation and technology driven business to scale-up in China.
ADC Therapeutics raises $200 Million in private placing to fund registrational trials of its lead anti-cancer drugs.